A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma - Related Studies

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

This study has been completed.

Study NCT00001296. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Melanoma

2	More general conditions related to this trial
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Nevi and Melanomas

3	Interventions listed in this trial
		melphalan
		tumor necrosis factor
		interferon-gamma

4	Additional drug interventions recognized in this trial
		Interferon Alfa-2b
		Interferon Type II
		Interferon-gamma, Recombinant
		Interferons

5	More general drug interventions related to this trial
		Alkylating Agents
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Infective Agents
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antiviral Agents
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		National Cancer Institute (NCI)